About

Professor Jonathan Golledge is Head of the Queensland Research Centre for Peripheral Vascular Disease and its pre-clinical arm The Vascular Biology Unit (VBU) at the School of Medicine and Dentistry, James Cook University. Professor Golledge joined JCU in 2002 and established the Vascular Biology Unit with the aim of carrying out research intended to be translated into improved management of aortic aneurysm and other peripheral vascular conditions. We continue to seek high quality students and researchers to join our group. Trained as a vascular specialist, Professor Golledge took 2 years out of specialist training to obtain experience in research techniques as part of a Cambridge MChir (Doctoral equivalent), UK. His research commitment is illustrated by a large number of presentations at International and National meetings and publications in peer-reviewed journals, including a large number in top specialised journals.

Professor Golledge holds a conjoint position between the School of Medicine and Dentistry and Queensland Health, where he works as a vascular surgeon. In addition to providing a high quality clinical service his principal aspiration is to improve management of peripheral vascular diseases. The research impact of this is evidenced by external grant support from the NIH, NHMRC, Queensland Government, NHF and other bodies. Of note in 2010 Professor Golledge led a successful bid to establish a NHMRC funded centre of research excellence for Peripheral Vascular Disease.

Research Disciplines
Socio-Economic Objectives
Honours
Fellowships
  • 2002 - Fellow of the Royal Australasian College of Surgeons
  • 1994 - Fellow of the Royal College of Surgeons of England
Memberships
  • 2012 - Editorial board member, Arteriosclerosis, Thrombosis and Vascular Biology
  • 2009 - Member of The Australian and International Stroke Genetics Collaboration
  • 2009 - Member of The Research Committee of the Faculty Medicine, Health and Molecular Sciences
  • 2007 - Member of the Board of Surgical Research of the Royal Australasian College of Surgeons
  • 2002 - Member of the Australian Vascular Biology Society
  • 2002 - Member of the School of Medicine Research Committee, James Cook University
  • 1996 - Member of the European Society of Vascular Surgery
  • 2002 to 2009 - Member of the ethics committee, The Mater Hospital, Townsville
  • 2003 to 2004 - Member of the Biological Sciences selection panel for internal grants, James Cook University
  • 1996 to 2001 - Member of the Vascular Surgical Society of Great Britain and Ireland
Other
  • 2012 - Editorial board Arteriosclerosis, Thrombosis and Vascular Biology
  • 2011 - Credentialling Committee The Townsville Hospital
  • 2007 - Editorial board member Atherosclerosis
  • 2003 - Reviewer The Lancet, Circulation, Arteriosclerosis, Thrombosis and Vascular Biology, Atherosclerosis, Journal of Vascular Surgery, European Journal of Vascular and Endovascular Surgery, American Journal of Cardiology, American Journal of Pathology
  • 2003 - External reviewer for numerous granting bodies including the National Health and Medical Research Council, National Heart Foundation and other international funding bodies such as the Welcome Trust
  • 2002 - Chairman of the Austalian and New Zealand Society of Vascular Surgery Research Group
  • 2000 - Reviewer Stroke
  • 1997 - Reviewer The Journal of Vascular Surgery and the European Journal of Vascular and Endovascular Surgery
  • 2003 to 2009 - Language Editor European Journal of Vascular and Endovascular Surgery
  • 2002 to 2007 - Chairman of the BMedSci Committee, James Cook University
Publications

These are the most recent publications associated with this author. To see a detailed profile of all publications stored at JCU, visit ResearchOnline@JCU. Hover over Altmetrics badges to see social impact.

Journal Articles
More

ResearchOnline@JCU stores 390+ research outputs authored by Prof Jon Golledge from 2003 onwards.

Current Funding

Current and recent Research Funding to JCU is shown by funding source and project.

National Health & Medical Research Council - Clinical Trials and Cohort Studies

The Metformin Aneurisym Trial (MAT)

Indicative Funding
$4,997,653 over 5 years
Summary
20 million people worldwide and 100,000 Australians have an abdominal aortic aneurysm (AAA). The main complication of AAA, aortic rupture, leads to 200,000 deaths/year worldwide. AAA prevalence and mortality rates in Australasia are 4-fold higher than the world average, so research to improve management is a key priorty. Most AAAs are detected when theya re small, when an effective treatment would prevent the need for surgery. There is currently no effective drug therapy for AA, and 70% of small AAAs grow to a size requiring surgical repair which carries inherent risks of death and major complications. A large amount of observational data from patients and laboratory models suggest that metformin may be an effective drug therapy for AAA. The metformin aneurysm trial (MAT) will be a large-scale, multi-centre randomised trail done as a collaboration between investigators in Australia, New Zealand, Swden and the United Kingdom across 55 sites over a 5 year trial period. Patients with AAA measuring between 39 and 49mmm in diameter will be enrolled over 24 months, assiged at random to 1500mn of metformin extended release (XR) or placebo each day followed for a mean of 3.5 years. The primary outcome will be AAA rupture or repair. The sample size of 1,954 will provide 90% pwer (p=0.05) to detect a 25% or greater reduction in the relative risk of the primary outcome. A positive finding from MAT would identify metformin as the first effective medical treatment for AAA. Since metformin is low cost, safe and available worldwide, the trial will have direct clinical implications for tens of millions of people around the world for whom no preventative therapy is currently available.
Investigators
Jon Golledge, Bruce Neal, Qiang Li, Gregory Jones, Matthew Bown, Anders Wanhainen, Richard Norman, Helen Monaghan, Dylan Morris and Joseph Moxon (College of Medicine & Dentistry, The George Institute for International Health, University of Otago, University of Leicester, University of Uppsala, Curtin University of Technology and Townsville Hospital and Health Services)
Keywords
Clinical Trial; Abdominal Aortic Aneurysm; Metformin

Queensland Health - Senior Clinical Research Fellowships

Peripheral Arterial Disease

Indicative Funding
$4,250,000 over 8 years
Summary
Developing novel therapies ad management pathways for Peripheral Arterial Disease. Aim 1. to assess the safety and efficacy of novel medications for PAD within carefully designed clinical trials and registries; Aim 2. to utilise clinical risk factors and novel biomarkers to develop models to better predict outcomes for PAD: Aim 3. To develop appropriate guidelines for the evidence-based management of PAD in Australia and assess novel ways to implement them within Queensland.
Investigators
Jonathan Golledge in collaboration with Paul Norman, Timothy Buckenham, Robert Fitridge, Bernard Bourke, Mark Nelson, Reinhold Muller, Anthony Leicht, Frances Quirk, Paula Clancy, Erik Biros, Corey Moran, Lesley Stainkey, Phillip Walker, Craig McLachlan, Yew Toh Wong and Melina Wilson (College of Medicine & Dentistry, The University of Western Australia, Christchurch Hospital, Queen Elizabeth Hospital, Gosford Hospital, Menzies School of Health Research, College of Public Health, Medical & Vet Sciences, College of Healthcare Sciences, Townsville - Mackay Medicare Local, The University of Queensland, University of Technology, Sydney, Southmead Hospital, Bristol and St George's Hospital Medical School)
Keywords
Peripheral Arterial Disease

Townsville Hospital and Health Service - Study Education Research Trust Account (SERTA)

Metformin in the mAnaGement of abdomInal aortiC aneurysm (MAGIC)

Indicative Funding
$50,000
Summary
MAGIC is a randomised trial to test metformin as a therapy for aortic aneurysm.
Investigators
Jon Golledge (College of Medicine & Dentistry)
Keywords
Abdominal Aortic Aneurism; Metformin

Heart Foundation - Vanguard Grant

Metformin for treating peripheral artery disease-related walking impairment (MERIT)

Indicative Funding
$75,000
Summary
Blockage of the lower limb arteries (peripheral artery disease; PAD) leads to severe leg pain, walking impairment, and a substantial risk of leg amputation and death. Approximately 200 million people worldwide and approximately 1 million Australians have blocked leg arteries. This problem has recognised treatment deficiencies in comparison to other common diseases, including the absence of effective medications to increase blood supply to the legs, reduce leg pain, improve walking ability and reduce the risk of major amputation. Multiple lines of evidence suggest that metformin, a cheap and safe medication, promotes formation of new vessels, improves microcirculation and muscle function, and limits pain. In preliminary studies, metformin significantly increased blood supply to the limb of a pre-clinical model of blocked leg arteries. We have also associated metformin prescription with a 4-fold reduction in the rate of major lower limb amputation in patients with blocked arteries. This placebo-controlled, randomised clinical trial will examine the efficacy of metformin in improving walking ability in patients with blocked leg arteries over 6 months. Positive findings from this trial will identify a new treatment for a problem that affects 10-20% of adults aged over 50 years.
Investigators
Jon Golledge, Dylan Morris and Joseph Moxon (College of Medicine & Dentistry and University of Oxford)
Keywords
peripheral artery disease; Clinical Trial; Medication

National Health & Medical Research Council - Practitioner Fellowship

Developing improved management for peripheral artery diseases

Indicative Funding
$569,219 over 5 years
Summary
This fellowship aims to address current deficiencies in the care of PAD patients by: Aim 1: Testing new PAD treatments in patient-relevant pre-clinical models; Aim 2: Examining the efficacy of new treatments in human clinical trials; Aim 3: Discovering novel targets for diagnostic tests, prognostic markers and treatments.
Investigators
Jon Golledge (College of Medicine & Dentistry)
Keywords
Peripheral Arterial Disease; Aortic Aneurysm

Townsville Hospital and Health Service - Study Education Research Trust Account (SERTA)

Peak Wall Stress as a prognostic indicator of abdominal Aortic Aneurysm rupture risk

Indicative Funding
$50,000 over 2 years
Summary
Abdominal Aortic Aneurysm (AAA) affects 20 million people worldwide and 100,000 people in Australia. Annually, AAA rupture leads to 200,000 deaths worldwide and 2000 deaths in Australia. In clinical practice, maximum AAA diameter is the preferred surrogate measure for disease progression and rupture risk, and is used to guide surgical intervention. Approximately 10% of AAAs will rupture before they reach the current threshold for repair, whereas 60% of large AAAs remain stable during their lifetime, suggesting that diameter alone is an imperfect tool to decide which AAAs require surgical intervention. The specific aims of the project are Aim 1: To investigate if PWS is greater in patients with ruptured compared to intact AAAs matched for diameter; Aim 2: To evaluate the impact of a common anti-hypertensive medication {Telmisartan) on PWS and rupture risk in patients with small AAAs.
Investigators
Tejas Singh, Jon Golledge and Joseph Moxon in collaboration with Thomas Gasser (College of Medicine & Dentistry and Royal Institute of Technology)
Keywords
Metformin; Abdominal Aortic Aneurysm; Ruptures

Townsville Hospital and Health Service - Study Education Research Trust Account (SERTA)

Assessment of the efficacy of a novel treatment for Peripheral Artery Disease (PAD)

Indicative Funding
$50,000 over 2 years
Summary
Blockage of leg arteries (peripheral artery disease - PAD) leads to severe exertional leg pain (intermittent claudication), impaired walking ability, reduced health-related quality of life, and high risk of amputation and death. Multiple lines of evidence suggest that metformin, a cheap and safe medication, promotes formation of new vessels, improves microcirculation and muscle function,s and limits pain.
Investigators
Jon Golledge, Joseph Moxon, Tejas Singh, Rachel Wong, Kunwargit Sangla and Veronica White (College of Medicine & Dentistry and Townsville Hospital and Health Services)
Keywords
Metformin; peripheral artery disease; Intermittent Claudication

Royal Australasian College of Surgeons RACS - James Ramsay Project Grant

Metformin in the management of abdominal aortic aneurysm (MAGIC)

Indicative Funding
$156,000 over 2 years
Summary
MAGIC will be the first trial to assess the value of metformin wiuth significant preliminary data to suggest it can slow AAA growth. This trial offers the possibility of identifying a new treatment modality for an increasingly common condition, which would markedly change clinical practice.
Investigators
Jon Golledge, Dylan Morris, Paul Norman, Joseph Moxon, Zanfina Ademi, Rachel Neale, Anders Wanhainen, Ronald Dalman, Robert Hinchliffe and Matthew Bown in collaboration with Anthony Dear, Bernard Bourke, Christopher Reid, Jason Jenkins, Derek Chew, Rachael Jones, Richard Norman and Stephen Colagiuri (College of Medicine & Dentistry, University of Oxford, The University of Western Australia, Monash University, Queensland Institute of Medical Research, University of Uppsala, Stanford University, University of Bristol, University of Leicester, Gosford Hospital, The University of Queensland, Flinders University, Curtin University of Technology and The University of Sydney)
Keywords
Aortic Aneurysm; Clinical Trials; Surgery

Diabetes Australia - General Grant

Testing a novel treatment for diabetes-associated ischemic foot ulceration

Indicative Funding
$60,000
Summary
5000 Australians with diabetes have a leg amputations each year. This project investigates a novel drug therapy approach to reducing the need for leg amputations within an established rodent model. The aim of the study is to assess if administration of a direct activator of adenosine-5'-monophosphate (AMP)-activated protein kinase (AMPK) will promote healing within a rat model of diabetes and limb ischaemia-associated foot ulceration
Investigators
Jon Golledge, Smriti Krishna and Joseph Moxon in collaboration with Jon Oakhill, Michelle Keske and Valerie Schini-Kerth (College of Medicine & Dentistry, St Vincent's Institute of Medical Research, Deakin University and Universite Louis Pasteur - Strasbourg I)
Keywords
peripheral artery disease; Diabetes; rodent model

National Health & Medical Research Council - Project Grant

Blocking the factor XII-kallikrein pathway to limit abdominal aortic aneurysm

Indicative Funding
$686,995 over 3 years
Summary
Abdominal aortic aneurysm (AAA) is estimated to be responsible for 2000 sudden deaths each year in Australia. AAAs can be readily identified when they are small but there are currently no effective medical therapies to limit complications in patients that have such AAAs. We hypothesise that interventions inhibiting the FXII-kallikrein pathway will limit progression of established AAAs within pre-clinical models and have other important secondary benefits such as the reduction of atherosclerosis progression.
Investigators
Jon Golledge and Corey Moran in collaboration with Daniel Sexton, Rhondda Jones, Paul Norman and Kosta Panousis (College of Medicine & Dentistry, Dyax Corporation, Division of Tropical Health & Medicine, The University of Western Australia and CSL)
Keywords
Abdominal Aortic Aneurysm; mouse models; Peripheral Vascular Disease; Biology; treatment planning

Vascular Foundation - Project Grant

Metformin in the management of abdominal aortic aneurysm (MAGIC)

Indicative Funding
$50,000
Summary
MAGIC will be the first trial to assess the value of metformin with significant preliminary data to suggest it can slow AAA growth. The trial offers the possibility of identifying a new treatment modality for an increasingly common condition, which would markedly change clinical practice.
Investigators
Jon Golledge and Paul Norman (College of Medicine & Dentistry and The University of Western Australia)
Keywords
Aortic Aneurysm; clinical trials; Surgery

Queensland Health - Junior Research Fellowship

Coding and non-coding circulating RNAs associated with the presence and rapid expansion of abdominal aortic aneurysms

Indicative Funding
$250,000 over 2 years
Summary
Deoxyribonucleic Acid, or DNA is the molecule that comprises genes. The mix of genes you have may mean you are likely to have, or be more prone to develop, particular conditions. The way the information encoded by DNA is converted into outcomes (such as a medical condition) is via the action of Ribonucleic Acid, or RNA. This project aims to identify RNAs in blood associated with the presence or rapid growth of abdominal aortic aneurysms - potentially lethal balloonings of the largest artery in the abdomen, the abdominal aorta. This may yield new methods of diagnosing and treating aneurysms.
Investigators
Vikram Iyer and Jon Golledge (College of Medicine & Dentistry)
Keywords
Abdominal Aortic Aneurysm; RNAs
Supervision

Advisory Accreditation: I can be on your Advisory Panel as a Primary or Secondary Advisor.

These Higher Degree Research projects are either current or by students who have completed their studies within the past 5 years at JCU. Linked titles show theses available within ResearchOnline@JCU.

Current
  • A small animal model for the creation of pre-aneurysmal change in the intracranial vasculature (Masters , Secondary Advisor)
  • Measuring Person-Centred Healthcare (PhD , Advisor Mentor)
  • Diabetic foot disease and prevention of its complications (PhD , Primary Advisor/AM/Adv)
  • Assessment and Intervention of Dietary Patterns in Patients with Peripheral Arterial Disease and Abdominal Aortic Aneurysm (PhD , Primary Advisor/AM/Adv)
  • Peak Wall Stress as a Prognostic Indicator of Abdominal Aortic Aneurysm Rupture Risk (PhD , Primary Advisor/AM/Adv)
  • Development and Implementation of Plasma Polymer Thin Films for Enhanced Biocompatibility in Medical Implants (PhD , Secondary Advisor)
  • Identification of Mediators Important in Determining Carotid Plaque Instability (PhD , Secondary Advisor)
Completed
Data

These are the most recent metadata records associated with this researcher. To see a detailed description of all dataset records, visit the JCU Research Data Catalogue.

Collaboration

The map shows research collaborations by institution from the past 7 years.
Note: Map points are indicative of the countries or states that institutions are associated with.

  • 5+ collaborations
  • 4 collaborations
  • 3 collaborations
  • 2 collaborations
  • 1 collaboration
  • Indicates the Tropics (Torrid Zone)

Connect with me
Share my profile
Share my profile:
jcu.me/jonathan.golledge

Email
Phone
Location
Advisory Accreditation
Advisor Mentor
Find me on…
Icon for NLA Trove People record Icon for Scopus Author page

Similar to me

  1. Dr Corey Moran
    College of Medicine & Dentistry
  2. Dr Tejas Singh
    College of Medicine & Dentistry
  3. Dr Joseph Moxon
    College of Medicine & Dentistry
  4. Dr Smriti Murali Krishna
    College of Medicine & Dentistry
  5. Dr Theophilus Emeto
    College of Public Health, Medical & Vet Sciences